Xenon Pharmaceuticals reported a strong Phase 3 outcome for azetukalner in focal onset seizures, exceeding analysts’ expectations and producing a materially larger placebo‑adjusted seizure reduction than projected. The company said the study met its primary endpoint with a safety profile consistent with prior trials and announced plans to file for FDA approval later this year. Investigators reported dose‑dependent efficacy and tolerability; the lower dose may present a favorable commercial balance given discontinuation rates at higher doses. Xenon emphasized the drug’s oral, once‑daily dosing and tolerability compared with some current anti‑seizure medicines. Investors reacted with a large share‑price gain. Xenon now faces regulatory review planning, labeling discussions, and the task of positioning azetukalner in an established antiseizure market where incremental efficacy and safety drive adoption.